Essential oils
Lavender oil, linalool and calcium channels: what Silexan research does—and does not—show
Explore linalool, linalyl acetate, voltage-dependent calcium channels and the difference between a standardised oral lavender preparation and aromatherapy oil.
Cell and synaptosome work supports calcium-channel modulation by a defined preparation; clinical trials studied standardised Silexan doses, not arbitrary inhalation or retail blends.
Compounds & molecular formulae
Linalool
C₁₀H₁₈O
A monoterpene alcohol common in lavender; stereochemistry and percentage vary by oil.
PubChem compound record ↗Linalyl acetate
C₁₂H₂₀O₂
An ester prominent in many lavender oils and a contributor to aroma.
PubChem compound record ↗Calcium-channel modulation in an experimental preparation
- Standardised lavender constituents reach a neuron preparation
- Voltage-dependent Ca²⁺ current is reduced
- Neurotransmitter release may change
- A clinical trial must test symptoms separately
The pathway is a mechanistic bridge, not proof that a diffuser or undiluted oil treats anxiety [1][2].
What lavender chemistry can tell us
Lavender oil is a mixture, often containing linalool and linalyl acetate alongside many minor constituents. The exact profile changes with species, harvest and processing. A formula such as C₁₀H₁₈O identifies linalool’s elemental composition; it does not identify its concentration in a particular bottle or predict a person’s response. Oxidised oils can also become more irritating or sensitising, so age and storage matter.
The voltage-dependent calcium-channel study
Schuwald and colleagues examined a standardised lavender preparation in synaptosomes, hippocampal neurons and channel-expressing cells [1]. They reported reduced calcium influx through several voltage-dependent calcium-channel types at concentrations they related to an 80 mg/day oral clinical preparation. The work provides a plausible molecular pathway, but it is not evidence that every lavender essential oil reaches those concentrations or that inhalation has the same pharmacokinetics.
Clinical Silexan trials are a separate evidence object
Silexan is a defined oral lavender oil preparation studied in controlled trials. A 2025 randomised placebo- and reference-controlled trial in mild-to-moderate major depression tested 80 mg/day Silexan, 50 mg/day sertraline or placebo for 56 days and reported small average differences from placebo [2]. Even when a standardised preparation shows a signal, the result cannot be transferred automatically to a diffuser, a topical bottle or an Enki product with unknown composition. The correct question is always: same preparation, same route, same population and same endpoint?
Safe aromatic use
Use lavender only for the purpose and concentration on its label. Do not swallow a concentrated essential oil, place it in the eyes or use it as a substitute for care for depression, anxiety or sleep problems. Ask a clinician about pregnancy, allergies, sedatives and children. Enki can confirm the available bottle and product instructions; it cannot turn an aroma preference into a diagnosis.
Sources & credits
- Schuwald et al. Lavender oil: anxiolytic properties via modulating voltage-dependent calcium channels (PLoS One, 2013) — Primary pharmacology study
- Lavender oil preparation Silexan in mild-to-moderate major depression (European Archives of Psychiatry and Clinical Neuroscience, 2025) — Randomised clinical trial
- NCCIH: Aromatherapy — Authoritative safety overview